![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Medicis Announces FDA Approval of Its NDA for Vanos
Medicis Announces FDA Approval of Its NDA for Vanos
The FDA has approved Medicis' new drug application for Vanos, a Class I corticosteroid for the treatment of plaque-type psoriasis.
Vanos is a patented corticosteroid formulation that embodies the heritage of Lidex. The unique formulation of Vanos provides doctors and patients with the convenience of a new, high-potency vehicle in the form of a cream for once or twice daily application.
The Class I corticosteroid market in the U.S. is approximately $329 million. Medicis anticipates launching Vanos to dermatologists in the quarter beginning April 2005.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct